EP3952893A1 - Systèmes et méthodes pour isoler des microvaisseaux à partir de tissu adipeux - Google Patents

Systèmes et méthodes pour isoler des microvaisseaux à partir de tissu adipeux

Info

Publication number
EP3952893A1
EP3952893A1 EP20786943.9A EP20786943A EP3952893A1 EP 3952893 A1 EP3952893 A1 EP 3952893A1 EP 20786943 A EP20786943 A EP 20786943A EP 3952893 A1 EP3952893 A1 EP 3952893A1
Authority
EP
European Patent Office
Prior art keywords
fat
enzyme
digestion
pellets
generate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP20786943.9A
Other languages
German (de)
English (en)
Other versions
EP3952893A4 (fr
Inventor
James HOYING
Hannah STROBEL
Sarah BUSHMAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Advanced Solutions Life Sciences LLC
Original Assignee
Advanced Solutions Life Sciences LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Solutions Life Sciences LLC filed Critical Advanced Solutions Life Sciences LLC
Publication of EP3952893A1 publication Critical patent/EP3952893A1/fr
Publication of EP3952893A4 publication Critical patent/EP3952893A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M45/00—Means for pre-treatment of biological substances
    • C12M45/09—Means for pre-treatment of biological substances by enzymatic treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
    • A61F2/06—Blood vessels
    • A61F2/062—Apparatus for the production of blood vessels made from natural tissue or with layers of living cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/35—Fat tissue; Adipocytes; Stromal cells; Connective tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M45/00—Means for pre-treatment of biological substances
    • C12M45/05—Means for pre-treatment of biological substances by centrifugation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0068—General culture methods using substrates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0653—Adipocytes; Adipose tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
    • G06N3/00—Computing arrangements based on biological models
    • G06N3/02—Neural networks
    • G06N3/08—Learning methods
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
    • C12N2509/10—Mechanical dissociation

Definitions

  • the present disclosure relates to a method for isolating microvessels from adipose tissue, and, more specifically, a method for isolating microvessels from adipose tissue utilizing an enriched or purified enzyme.
  • a practiced method of isolation of cells, including microvessels, from tissues utilizes crude preparations of tissue disassociated enzymes to disassociate the tissue into respective cellular constituents.
  • methods and systems may isolate microvessels using an enriched or purified enzymes to dissociate tissue.
  • the systems and methods may include a double digestion feature and/or an immediate post digestion wash feature.
  • a system to isolate microvessels using enriched enzymes to dissociate tissue may include one or more processors, a non-transitory memory communicatively coupled to the one or more processors, and machine readable instructions stored in the non-transitory memory.
  • the enriched enzyme may include an enriched or purified enzyme.
  • the machine readable instructions may cause the system to perform at least the following, as one or more protocols, when executed by the one or more processors: digest, in a first digestion, a minced adipose with an enriched enzyme to generate a first fat-enzyme solution, centrifuge the first fat-enzyme solution from the first digestion in a first centrifuge operation to generate one or more first pellets and a top fat layer disposed above the one or more first pellets, digest, in a second digestion, the top fat layer with the enriched enzyme to generate a second fat-enzyme solution, centrifuge the second fat-enzyme solution from the second digestion in a second centrifuge operation to generate one or more second pellets, and pass one or more portions of the one or more first pellets and the one or more second pellets through one or more screens to generate a plurality of isolated microvessels.
  • a method to isolate microvessels using enriched enzymes to dissociate tissue may include digesting, in a first digestion, a minced adipose with an enriched enzyme to generate a first fat-enzyme solution, centrifuging the first fat-enzyme solution from the first digestion in a first centrifuge operation to generate one or more first pellets and a top fat layer disposed above the one or more first pellets, and digesting, in a second digestion, the top fat layer with the enriched enzyme to generate a second fat-enzyme solution.
  • the method may further include centrifuging the second fat-enzyme solution from the second digestion in a second centrifuge operation to generate one or more second pellets, and passing one or more portions of the one or more first pellets and the one or more second pellets through one or more screens to generate a plurality of isolated microvessels.
  • a method to isolate microvessels using enriched enzymes to dissociate tissue may include digesting, in a first digestion, a minced adipose with an enriched enzyme to generate a first fat-enzyme solution, using an additional enzyme as a catalyst for digestion of the first fat-enzyme solution, centrifuging the first fat-enzyme solution from the first digestion in a first centrifuge operation to generate one or more first pellets and a top fat layer disposed above the one or more first pellets, and digesting, in a second digestion, the top fat layer with the enriched enzyme to generate a second fat-enzyme solution.
  • the method may further include washing the second fat-enzyme solution with an enzyme inhibitor in a post digestion wash, centrifuging the second fat-enzyme solution from the second digestion in a second centrifuge operation to generate one or more second pellets, and passing one or more portions of the one or more first pellets and the one or more second pellets through one or more screens to generate a plurality of isolated microvessels.
  • the enzyme inhibitor of the post-digestion wash may include one or more peptide inhibitors, one or more small molecule inhibitors, one or more native matrix material inhibitors, or combinations thereof.
  • FIG. 1 illustrates a flow chart of a method to isolate microvessels using enriched or purified enzymes to dissociate tissue, according to one or more embodiments as shown and described herein;
  • FIG. 2 illustrates a flow chart of another method to isolate microvessels using enriched or enzymes to dissociate tissue, according to one or more embodiments as shown and described herein;
  • FIG. 3 schematically illustrates a system to implement a computer-based process to automate the methods of the flow charts of FIGS. 1-2, according to one or more embodiments as shown and described herein.
  • systems and a methods are described to isolate intact and functional microvessels using enriched or purified enzymes to dissociate tissue, such as adipose tissue or other tissues. While such enzymes may be described as enriched herein, it is contemplated and within the scope of this disclosure that purified enzymes are a type of enriched enzyme compared to a crude enzyme alone without enrichment or purification.
  • the systems and methods may include use of a double digestion of minced adipose, as described in greater detail below.
  • systems and methods may include use of an immediate post-digestion wash, as further described in greater detail below.
  • minced adipose may undergo a single digestion with the crude enzymes and be centrifuged to result in underlying pellets and a disposable top layer.
  • the disposable top layer is discarded, and one or more portions of the underlying pellets may be passed through a screen to disassociate tissue and isolate microvessels.
  • the systems and methods described herein are directed to a double digestion feature in a method to isolate microvessels using enriched or purified enzymes to dissociate tissue, the double digestion feature directed to a second digestion and use of the top layer resulting from a first digestion.
  • the enriched or purified enzymes comprise enriched or purified collagenase.
  • the enriched or purified enzymes comprise chromatographically enriched or purified collagenase.
  • the enriched or purified enzymes comprise a low protease, enriched collagenase product from Clostridium histolyticum useful for isolating cells from tissue.
  • the enriched or purified enzymes comprise Collagenase Gold or DEGold Collagenase or Collagenase HA (as may be commercially available through VITACYTE of Indianapolis, Indiana).
  • the enriched or purified enzymes may comprise other bacterial sources, such as Vibrio, and/or mammalian collagenases.
  • a flow chart of a method 100 to isolate microvessels using enriched or purified enzymes to dissociate tissue In block 102, minced adipose undergoes a first digestion with enriched or purified enzymes to result in a first fat-enzyme solution. In embodiments, adipose is minced, such as by hand mixing or via a liposuction cannula and digested with the enriched or purified enzymes.
  • Embodiments of shredding (e.g., mincing) techniques to mince adipose tissue may include use of other mechanical techniques as understood to one of ordinary skill in the art.
  • Such shredding technique may coordinate to receive fat for shredding from one or more procedures such as liposuction (e.g., lipoaspiration) or abdominoplasty.
  • liposuction e.g., lipoaspiration
  • abdominoplasty e.g., a surgical cannula may be used to collect fat as lipoaspirates that is then shredded.
  • abdominoplasty chunks of fat may be removed and isolated and further shredded.
  • the first fat-enzyme solution may further include use of another enzyme as a contaminant to assist the enriched or purified enzyme(s) as a catalyst for digestion.
  • the another enzyme may be, but is not limited to, deoxyribonuclease (DNase), which is a nuclease enzyme capable of hydrolyzing phosphodiester bonds that link nucleotides and that, more particularly, catalyze a hydrolytic cleavage of phosphodiester linkages in a DNA backbone to degrade DNA.
  • DNase deoxyribonuclease
  • a digestion flask may be used including a matching volume of fat to a volume of enriched or purified enzyme and a stir bar may be used that may be Teflon or steel coated.
  • the digestion flask may be shaken or not shaken for 8-10 minutes at 37°C in a water bath.
  • the first fat-enzyme solution of block 102 is centrifuged in a first centrifuge operation to result in one or more pellets from the first centrifuge operation and a top fat layer disposed above the one or more pellets.
  • the first centrifuge operation allows for a separation of fat and the isolate including microvessels.
  • the top layer resulting from the first centrifuge operation undergoes a second digestion with enriched or purified enzymes to result in a second fat- enzyme solution.
  • the top layer is a top fat layer that is digested in the second digestion with a fresh enriched or purified enzyme to fully release the
  • microvessels from the top fat layer are microvessels from the top fat layer.
  • the second fat-enzyme solution is centrifuged in a second centrifuge operation to result in one or more pellets from the second centrifuge operation.
  • a lipid/upper layer e.g., such as an upper lipid layer
  • supernatant of the second fat-enzyme solution is aspirated off to leave behind the one or more pellets at a bottom of a tube.
  • portions of the one or more pellets from the first centrifuge operation and from the second centrifuge operation as resulting pellets are passed through one or more screens as isolated microvessels.
  • the resulting pellets are washed with a gelatin solution and passed through two screens to collect the microvessels.
  • microvessel enzymes may be inhibited and/or quenched to prevent or minimize collagen degradation of the microvessels via cryopreservation and/or a post-digestion wash with an enzyme inhibitor, as described in greater detail below with respect to FIG. 2.
  • the cryopreservation may preserve the microvessels for up to a time period, such as a time period of a month.
  • Collagenase as the enriched or purified enzyme with 30 mg DNase in 0.1% DPBS as a balanced salt solution to handle and culture mammalian cells.
  • 10 mis of the first fat-enzyme solution is added to 10 mis of fat (e.g., the minced adipose) in a first flask, such that 15 mg of the enriched or purified enzyme is used (e.g., l.Ox enzyme mix).
  • 7.5 mis of the first fat-enzyme solution is added to the other 10 mis of fat such that 7.5 mg of the enriched or purified enzyme is used (e.g., 0.5x enzyme mix).
  • both flasks are digested one minute of shaking and 7 minutes without shaking at 37°C in a water bath for 8 minutes. Both flasks still retain tissue chunks.
  • the material of both flasks are centrifuged in the first centrifuge operation.
  • the 1 0x enzyme mix results in a larger pellet than the 0.5x enzyme mix.
  • Fat tissue remains at a top layer for each centrifuged mix.
  • the top layer is transferred to a new flask and the remaining enzyme of the first fat- enzyme solution is added in at 7.5 mis and redigested. This redigestion acts as a second digestion feature and includes 8 minutes of shaking, resulting in quality tissue with mostly adipocytes at top.
  • the l.Ox enzyme mix results in cell clusters with no microvessels in the pellet and the 0.5x enzyme mix results in larger cell clusters with no microvessels in the pellet.
  • block 106 post the second digestion, and after the centrifuging of block 108 and microvessel isolation of block 110, a considerable number of microvessels result, many of which are long. At 45 count divided by 0.02 ml and multiplied by 40 ml, a result of 90,0000 microvessels is estimated.
  • microvessels are pelleted and frozen (e.g., cryopreserved) in freeze media 1 ml aliquots at -20°C for 2-3 hours, then -80°C if in foam container or directly into -80°C with a cooling of -l°C/minute.
  • the l.Ox enzyme mix may be digested in block 102 for 16 minutes.
  • FIG. 2 illustrates a flow chart of another method 200 to isolate microvessels using enriched or purified enzymes to dissociate tissue.
  • the method 200 is similar to the method 100 of FIG. 1 with an additional option in step 208 to include use of a post digestion wash, which occurs before the second centrifuge.
  • the blocks 202, 204, 206, and 210 of FIG. 2 are similar to blocks 102, 104, 106, and 110 as described above.
  • the post-digestion wash may be a feature immediate to the digestion that includes use of a 0.01% porcine gelatin.
  • the post- digestion wash may include use of an enzyme inhibitor.
  • the enzyme inhibitor may comprise classes of inhibitors such as, but not limited to, peptide inhibitors, small molecule inhibitors, native matrix material inhibitors, or combinations thereof.
  • the native matrix material inhibitors may include, but not be limited to, collagen gels, fibrin, elastin, gelatin, or combinations thereof.
  • Example 2 starts with sterile supplies and follows best biosafety level 2 (BSL-2) laboratory practices and aseptic technique.
  • the supplies may include the following:
  • BSA bovine serum albumin protein
  • Example 2 The procedure of Example 2 with reference to FIG. 2 follows: [0029] The 20 mih nylon screen is placed in a petri dish containing 20 ml of BSA- PBS for later use. For block 202, no more than 35 ml of fat is transferred to a 50 ml conical tube. Up to 4 conical tubes of fat can be used at one time. The volume of each tube is brought to 50 ml with HBSS. The tubes are inverted to wash, and centrifuged at 400 g for 4 min to result in fat at the top of the conical tube as a top fat layer.
  • the top fat layer is moved to fresh 50 ml conical tubes (up to 35 ml per new tube), and the volume is brought up to 50 ml with HBSS, and the fresh tubes are centrifuged at 400 g for 4 min. No more than 30 ml of fat is placed per 125 mL Erlenmeyer flask(s) containing a small spin bar.
  • a first fat-enzyme solution is prepared through a measurement and preparation of Collagenase Gold and DNase solution.
  • the first fat-enzyme solution is made containing 1 mg/ml of each enzyme in BSA-PBS (i.e., 15 mg collagenase and 15 mg DNase in 15 ml BSA-PBS).
  • a volume equal to the volume of fat to be digested is prepared, plus 0.5X ml extra.
  • a 0.2 pm SteriFlip filter is used to sterilize the first fat- enzyme solution.
  • the first fat-enzyme solution is transferred to 50 ml conical tubes (no more than 35 ml per tube), and the volume of each tube is brought to 50 ml with BSA-PBS.
  • 250 pi of sterile 2% gelatin is added to each conical tube (for a final concentration of 0.01% gelatin) and the first centrifuge operation occurs at 400 g for 4 minutes.
  • a pellet results in the conical tube containing blood cells, clumps of stromal cells, and microvessels.
  • the fat in the conical tube is collected at the top (where the fat will appear undigested as a top fat layer) and transferred to the same 50 ml Erlenmeyer flask with stir bar.
  • the same volume of fresh enzyme mix as a second fat-enzyme solution is added as with the first digestion (i.e., 15 mis if started with 15 ml of fat).
  • the cap of the flask is wrapped in parafilm, and the flask is incubated with shaking in a 37°C water bath for 8 minute in a second digestion.
  • the 50 ml conical tubes may be taken to aspirate the remaining liquid on top of each pellet to leave approximately 5 ml above the pellet.
  • the pellet may be re suspended and transferred to a petri dish.
  • the resulting fat-enzyme solution may be transferred to a 50 ml conical tube and topped off to 50 ml with BSA-PBS. Further, 250 m ⁇ of 2% gelatin may be added to each conical tube (for a final concentration of 0.01% gelatin) and centrifuged in a second centrifuge operation at 400 g for 4 minutes. The resulting pellet will contain the isolated microvessels and un-digestable matrix elements. The lipid/upper layer and supernatant may be aspirated off to leave approximately 5 ml above the pellet disposed at the bottom of the tube.
  • each pellet is re-suspended and 25-30 ml of BSA-PBS is added.
  • the pellets are added to the petri dish including the microvessels (e.g., pellets) from the first digestion.
  • the metal screen is placed on top of a new petri dish, and the 500 pm nylon mesh filter is placed on top of the metal screen.
  • the microvessel suspension is slowly pipetted from the dish onto the 500 pm screen to remove pieces of undigested tissue from the suspension.
  • the petri is rinsed with 10 ml BSA-PBS and pipetted onto the 500 pm screen.
  • the screen is rinsed by pipetting an additional 20 ml of BSA-PBS onto the screen to wash any microvessels through the screen that are adhered to the screen or any tissue chunks.
  • the 500 pm screen is discarded, and the wire support is moved to a new 10 cm dish. At this stage, the microvessels have passed through the screen and are in the dish.
  • the 20 pm nylon mesh filter is placed on top of the wire mesh screen and centered over the new underlying dish.
  • the filtered microvessel suspension now in the petri dish used for the 500 pm screening, is pipetted through the 20 pm screen in, for example, concentric circles. If the suspension begins to move very slowly through the screen such that a puddle is forming on the screen and taking time to move through, stop this step and proceed to the next step. This slow movement and puddle indicates a high yield of microvessels such that all the single cells may not be able to be washed out if the step is continued. Instead, retrieve a second 20pm screen, soak briefly in BSA-PBS, and continue with pipetting step using as many additional screens as is necessary. The original dish is rinsed with 10 ml of BSA-PBS to remove any remaining microvessels, and pipette onto the screen.
  • the screen is rinsed again by gently pipetting 20 ml BSA-PBS in concentric circles to wash out any remaining single cells, taking care not to spill over the edge of the screen.
  • the microvessels are trapped on top of the screen with single cells having passed through the screen.
  • the 20pm nylon mesh filter is slid off the wire mesh and into the petri dish containing 20 mL BSA-PBS that was originally used to soak the screen, microvessel-side up.
  • the 20pm mesh is allowed to soak for 10 minutes.
  • the petri dish is gently shaken back and forth to dislodge microvessels from the nylon mesh filter.
  • the top of the nylon screen is washed by pipetting up some of the microvessel suspension around the screen, and then pipetted down onto the screen. This suspension is transferred to a 50 ml tube.
  • the wash is repeated several times by pipetting 10 ml at a time of fresh BSA-PBS onto the screen and then moving the rinse to the 50 ml tube.
  • the edges of the screen well should be rinsed as well.
  • the screen should be checked under the microscope to ensure all microvessels have been removed and these removal steps repeated if necessary until all the microvessels have been removed from the screen.
  • the resulting, isolated microvessels should at this stage be in the 50 ml conical tube.
  • a counting procedure may include first determining that the 50 ml conical tube top is securely tightened. Next, the tube containing the fragment suspension is gently inverted 2-3 times to keep the microvessels distributed evenly in the solution. Two 20 pL samples of the suspension are removed immediately after tube inversions and streaked across a glass slide. The pipette tips are changed between each sample as glass slides are not sterile. Further, it should be determined that no large drops are on the pipette tip before streaking on the slide. Under a microscope, the microvessels are counted in each streak.
  • Microvessels that are stripped (no longer have cells attached) should not be counted.
  • Each branch of large vessels should be counted as a separate vessel.
  • the total number of microvessels may be calculated through the following Equation 1 :
  • Total Microvessels (average fragment count from the two 20 m ⁇ samples) * [(volume of suspension in the 50 ml tube) / 0.02)]
  • the fragment suspension may be centrifuged at 400 g for 4 minutes, which may be done while counting the microvessels.
  • the supernatant may be decanted or aspirated to leave approximately 100 pL of solution above the microvessel pellet.
  • the 100 pL of solution may be gently pipetted to loosen the microvessel fragments.
  • the resulting, isolated microvessels may be frozen as well.
  • the cryo-tubes may be prepared such at that all tubes are labelled with their contents (human
  • microvessels MV
  • stromal vascular fraction SVF
  • DMEM fetal bovine serum
  • DMSO Dimethylsulfoxide
  • the cryo-tubes are placed into a freezing container (e.g., MR. FROSTY as commercially available from THERMO FISHER SCIENTIFIC) and moved immediately to a -80°C freezer. If no freezing container is available, a foam shipping container can be used instead. If a foam shipping container is used, the cry-tubes may be placed in -20°C for 2-4 hours and then in a -80°C freezer or other freezing device as per instructions. After 24 hours, the vials are transferred to liquid N2 for storage for retainability.
  • a freezing container e.g., MR. FROSTY as commercially available from THERMO FISHER SCIENTIFIC
  • a foam shipping container can be used instead. If a foam shipping container is used, the cry-tubes may be placed in -20°C for 2-4 hours and then in a -80°C freezer or other freezing device as per instructions. After 24 hours, the vials are transferred to liquid N2 for storage for retainability.
  • the enriched or purified enzyme methods described herein provide for a development of novel isolation, culture, and aliquoting standards to isolate human (or other) microvessels using enriched or purified enzymes to dissociate tissue.
  • Other embodiments are within the scope of this disclosure.
  • a yield is not as a high as when using a double digestion.
  • a yield is not as a high as when using a double digestion and a fair amount of fat remains undigested.
  • a high yield results after the second digestion with a good microvessel quality. Repeating such a double digestion multiple times results in consistent yields and good quality across different fat sources, such as three different fat sources.
  • the collagen may quickly degrade with microvessel collapse, likely due to residual collagenase carryover on the microvessel isolate.
  • microvessels frozen for more than or equal to four weeks did not result in degraded collagen.
  • the post-solution wash of block 208 immediate to the second digestion of block 206 and prior the second centrifuge operation maintains collagen integrity throughout culture duration, results in high microvessel yields, and prevents collagen degradation.
  • Other wash protocols are tested as well in various other examples.
  • a 0.01% gelatin wash after screening for 5 minutes slows collagen degradation but does not stop it and results in lower quality microvessel growth.
  • a 0.01% gelatin added to all screens/washes after digestions diminishes yield due to gelatin-dependent clumping of microvessels that are screened out, though the collagen did not degrade.
  • a 0.01% gelatin wash after screen for 20 minutes maintains collagen integrity throughout culture duration.
  • a wash after the enzyme digestion with 0.1% gelatin for one wash only results in high yields, good microvessel quality, and collagen that does not degrade.
  • the microvessel growth may be lot dependent and involve expensive and time consuming lot testing.
  • Use of a serum-free medium (SFM) allows for a defined, cost effective process that is not lot dependent and does not include animal products, which is useful for human studies.
  • Use of Sato SFM and 10 ng/ml VEGF results in no microvessel growth.
  • Use of a corrected dosing calculation in a recipe for components in addition to the Sato SFM and 10 ng/ml VEGF results in sluggish microvessel growth.
  • microvessels are smaller than tested rat microvessels, resulting in a lower density for a same number of microvessels/mL, where a high density is desired for robust microvessel growth.
  • a higher microvessel number per aliquot allows for an easier uniform suspension at thawing and more accurate counts, and a minimum aliquot size of 20K microvessels may provide for easier use and consistent handling.
  • a minimum density of 80K microvessel/mL may be used.
  • some batches of fat contain muscle cells (e.g., myocytes) that can rupture during culture to result in microvessel death.
  • muscle cells e.g., myocytes
  • a Percoll centrifugation may separate out cells of different sizes, though microvessels of similar density to myocytes will not separate.
  • Myocytes may stick to plastic, so only the top three-quarters of the isolate may be screened and the myocytes captured by plastic, resulting in a substantially lower myocyte count, good microvessel growth, and a slightly lower microvessel yield.
  • a tissue culture adherent plastic may be utilized to further encourage myocyte adherence.
  • FIG. 3 illustrates a system 300 to implement computer-based control schemes to automate the methods 100, 200 of the flow charts of FIGS. 1-2.
  • the system 300 may be implemented along with using a graphical user interface (GUI) 202 that is accessible at a user workstation (e.g., a computing device 324), for example.
  • GUI graphical user interface
  • the computing device 324 may be a smart mobile device, which may be a smartphone, a tablet, or a like portable handheld smart device.
  • the computing device 324 includes a processor, a memory communicatively coupled to the processor, and machine readable instructions stored in the memory.
  • the machine readable instructions may cause the system 300 to, when executed by the processor, follow one or more of the blocks of the methods 100, 200 of FIGS. 1-2 such that one or more steps of the methods 100, 200 may be automated.
  • the machine readable instructions may cause the system 300 to, when executed by the processor, follow one or more control schemes as set forth in the one or more processes described herein.
  • the system 300 includes a communication path 302, one or more processors 304, a memory component 306, a software tool component 312, a storage or database 314 that may include one or more protocols as described herein, an artificial intelligence component 316, a network interface hardware 318, a server 320, a network 322, and at least one computing device 324.
  • a communication path 302 one or more processors 304, a memory component 306, a software tool component 312, a storage or database 314 that may include one or more protocols as described herein, an artificial intelligence component 316, a network interface hardware 318, a server 320, a network 322, and at least one computing device 324.
  • the system 300 is implemented using a wide area network (WAN) or network 322, such as an intranet or the Internet, or other wired or wireless communication network that may include a cloud computing-based network configuration.
  • the workstation computing device 324 may include digital systems and other devices permitting connection to and navigation of the network, such as the smart mobile device 200.
  • Other system 300 variations allowing for communication between various geographically diverse components are possible.
  • the lines depicted in FIG. 3 indicate communication rather than physical connections between the various components.
  • the system 300 includes the communication path 302.
  • the communication path 302 may be formed from any medium that is capable of transmitting a signal such as, for example, conductive wires, conductive traces, optical waveguides, or the like, or from a combination of mediums capable of transmitting signals.
  • the communication path 302 communicatively couples the various components of the system 300.
  • the term“communicatively coupled” means that coupled components are capable of exchanging data signals with one another such as, for example, electrical signals via conductive medium, electromagnetic signals via air, optical signals via optical waveguides, and the like.
  • the system 300 includes the processor 304.
  • the processor 304 can be any device capable of executing machine readable instructions.
  • the processor 304 may be a controller, an integrated circuit, a microchip, a computer, or any other computing device.
  • the processor 304 is communicatively coupled to the other components of the system 300 by the communication path 302.
  • the communication path 302 may communicatively couple any number of processors with one another, and allow the modules coupled to the communication path 302 to operate in a distributed computing environment.
  • each of the modules can operate as a node that may send and/or receive data.
  • the processor 304 may process the input signals received from the system modules and/or extract information from such signals.
  • the system 300 includes the memory component 306 which is coupled to the communication path 302 and communicatively coupled to the processor 304.
  • the memory component 306 may be a non-transitory computer readable medium or non-transitory computer readable memory and may be configured as a nonvolatile computer readable medium.
  • the memory component 306 may comprise RAM, ROM, flash memories, hard drives, or any device capable of storing machine readable instructions such that the machine readable instructions can be accessed and executed by the processor 304.
  • the machine readable instructions may comprise logic or
  • the machine readable instructions may be written in a hardware description language (HDL), such as logic implemented via either a field- programmable gate array (FPGA) configuration or an application-specific integrated circuit (ASIC), or their equivalents.
  • HDL hardware description language
  • FPGA field- programmable gate array
  • ASIC application-specific integrated circuit
  • the methods described herein may be implemented in any conventional computer programming language, as pre-programmed hardware elements, or as a combination of hardware and software components.
  • the system 300 may include the processor 304 communicatively coupled to the memory component 306 that stores instructions that, when executed by the processor 304, cause the processor to perform one or more functions as described herein.
  • the system 300 comprises the display such as a GUI on a screen of the computing device 324 for providing visual output such as, for example, information, graphical reports, messages, or a combination thereof.
  • the computing device 324 may include one or more computing devices across platforms, or may be communicatively coupled to devices across platforms, such as smart mobile devices 200 including smartphones, tablets, laptops, and/or the like.
  • the display on the screen of the computing device 324 is coupled to the communication path 302 and communicatively coupled to the processor 304. Accordingly, the communication path 302 communicatively couples the display to other modules of the system 300.
  • the display can include any medium capable of transmitting an optical output such as, for example, a cathode ray tube, light emitting diodes, a liquid crystal display, a plasma display, or the like. Additionally, it is noted that the display or the computing device 324 can include at least one of the processor 304 and the memory component 306. While the system 300 is illustrated as a single, integrated system in FIG. 3, in other embodiments, the systems can be independent systems.
  • the system 300 comprises the software tool component 312 to automate steps of one or more protocols or methods as described herein and the artificial intelligence component 316 to train and provide machine learning capabilities to a neural network that may provide machine learning to automatically improve upon and modify automated protocols or methods applied as described herein to result in more accurate and consistent and higher yielding microvessel growth and isolation.
  • machine readable instructions cause the system 300 to perform at least the following when executed by the one or more processors 304: apply the artificial intelligence component 316 to train a neural network model used by the system 300 to automate one or more protocols of the system 300 as described herein, and apply machine learning to the neural network model via the artificial intelligence component 316 to modify the one or more protocols over time based on historical data associated with the one or more protocols of the system 300 to result in higher yielding microvessel growth and isolation of increasing accuracy and consistency by the system 300 over time.
  • the software tool component 312 and the artificial intelligence component 316 are coupled to the communication path 302 and communicatively coupled to the processor 304.
  • the processor 304 may process the input signals received from the system modules and/or extract information from such signals.
  • the artificial intelligence component 316 which is able to leverage a cloud computing-based network configuration such as the cloud to apply Machine Learning and Artificial Intelligence.
  • This machine learning application may create models that can be applied by the system 300, to make it more efficient and intelligent in execution.
  • the artificial intelligence component 316 may include components selected from the group consisting of an artificial intelligence engine, Bayesian inference engine, and a decision-making engine, and may have an adaptive learning engine further comprising a deep neural network learning engine.
  • the system 300 includes the network interface hardware 318 for
  • the network interface hardware 318 is coupled to the communication path 302 such that the communication path 302 communicatively couples the network interface hardware 218 to other modules of the system 300.
  • the network interface hardware 318 can be any device capable of transmitting and/or receiving data via a wireless network. Accordingly, the network interface hardware 318 can include a communication transceiver for sending and/or receiving data according to any wireless communication standard.
  • the network interface hardware 318 can include a chipset (e.g., antenna, processors, machine readable instructions, etc.) to communicate over wired and/or wireless computer networks such as, for example, wireless fidelity (Wi-Fi), WiMax, Bluetooth, IrDA, Wireless USB, Z-Wave, ZigBee, or the like.
  • Wi-Fi wireless fidelity
  • WiMax wireless fidelity
  • Bluetooth IrDA
  • Wireless USB Wireless USB
  • Z-Wave ZigBee
  • ZigBee ZigBee
  • data from various applications running on the computing device 324 can be provided from the computing device 324 to the system 300 via the network interface hardware 318.
  • the computing device 324 can be any device having hardware (e.g., chipsets, processors, memory, etc.) for communicatively coupling with the network interface hardware 318 and a network 322.
  • the computing device 324 can include an input device having an antenna for communicating over one or more of the wireless computer networks described above.
  • the network 322 can include any wired and/or wireless network such as, for example, wide area networks, metropolitan area networks, the Internet, an Intranet, the cloud 323, satellite networks, or the like. Accordingly, the network 322 can be utilized as a wireless access point by the computing device 324 to access one or more servers (e.g., a server 320).
  • the server 320 and any additional servers such as a cloud server generally include processors, memory, and chipset for delivering resources via the network 322. Resources can include providing, for example, processing, storage, software, and information from the server 320 to the system 300 via the network 322. Additionally, it is noted that the server 320 and any additional servers can share resources with one another over the network 322 such as, for example, via the wired portion of the network, the wireless portion of the network, or combinations thereof.
  • variable being a“function” of a parameter or another variable is not intended to denote that the variable is exclusively a function of the listed parameter or variable. Rather, reference herein to a variable that is a“function” of a listed parameter is intended to be open ended such that the variable may be a function of a single parameter or a plurality of parameters.
  • recitations herein of“at least one” component, element, etc. should not be used to create an inference that the alternative use of the articles“a” or“an” should be limited to a single component, element, etc.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Sustainable Development (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Rheumatology (AREA)
  • Physics & Mathematics (AREA)
  • Theoretical Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Artificial Intelligence (AREA)
  • Biophysics (AREA)
  • Software Systems (AREA)
  • Mathematical Physics (AREA)
  • General Physics & Mathematics (AREA)
  • Computing Systems (AREA)
  • Evolutionary Computation (AREA)
  • Data Mining & Analysis (AREA)
  • Computational Linguistics (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)

Abstract

L'invention concerne des méthodes et systèmes pour isoler des microvaisseaux à l'aide d'une enzyme enrichie ou purifiée pour dissocier le tissu. Les systèmes et méthodes comprennent une seconde digestion visant à digérer une couche supérieure, obtenue par une première opération de digestion et une première opération de centrifugation, à l'aide de l'enzyme enrichie ou purifiée afin de générer une seconde solution formée de lipides et de l'enzyme, une seconde opération de centrifugation, et l'isolement des microvaisseaux à partir des culots générés par les première et seconde opérations de centrifugation. Les systèmes et méthodes peuvent comprendre le lavage de la seconde solution lipides-enzyme à l'aide d'un inhibiteur d'enzyme dans un lavage post-digestion.
EP20786943.9A 2019-04-10 2020-04-09 Systèmes et méthodes pour isoler des microvaisseaux à partir de tissu adipeux Withdrawn EP3952893A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962831765P 2019-04-10 2019-04-10
PCT/US2020/027354 WO2020210415A1 (fr) 2019-04-10 2020-04-09 Systèmes et méthodes pour isoler des microvaisseaux à partir de tissu adipeux

Publications (2)

Publication Number Publication Date
EP3952893A1 true EP3952893A1 (fr) 2022-02-16
EP3952893A4 EP3952893A4 (fr) 2023-01-04

Family

ID=72749126

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20786943.9A Withdrawn EP3952893A4 (fr) 2019-04-10 2020-04-09 Systèmes et méthodes pour isoler des microvaisseaux à partir de tissu adipeux

Country Status (8)

Country Link
US (1) US20200325436A1 (fr)
EP (1) EP3952893A4 (fr)
JP (1) JP2022527383A (fr)
KR (1) KR20210149752A (fr)
AU (1) AU2020271073A1 (fr)
CA (1) CA3134840A1 (fr)
IL (1) IL287040A (fr)
WO (1) WO2020210415A1 (fr)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002357135C1 (en) * 2001-12-07 2009-01-22 Macropore Biosurgery, Inc. Systems and methods for treating patients with processed lipoaspirate cells
WO2006062989A1 (fr) * 2004-12-07 2006-06-15 Bacterin International, Inc. Systeme de culture cellulaire tridimensionnel
US20130034524A1 (en) * 2011-08-03 2013-02-07 Siamak Agha-Mohammadi Non-Enzymatic Method for Harvesting Adipose-Derived Stromal Cells and Adipose-Derived Stem Cells from Fat and Lipo-Aspirate
EP2714887A1 (fr) * 2011-08-29 2014-04-09 Stempeutics Research Private Limited Système pour isoler des cellules de fraction stroma-vasculaire (svf) de tissu adipeux et son procédé
WO2013086183A1 (fr) * 2011-12-07 2013-06-13 Huang Lotien R Procédé et dispositif pour le traitement d'échantillons
WO2017218202A1 (fr) * 2016-06-14 2017-12-21 Beth Israel Deaconess Medical Center, Inc. Plateforme de distribution numérique, automatisée, pour test de sensibilité antimicrobienne des microdilutions
WO2018031654A1 (fr) * 2016-08-09 2018-02-15 Arteriocyte, Inc. Dispositifs et procédés de récolte des segments de microvaisseau dérivés de graisse

Also Published As

Publication number Publication date
WO2020210415A1 (fr) 2020-10-15
AU2020271073A1 (en) 2021-11-04
EP3952893A4 (fr) 2023-01-04
IL287040A (en) 2021-12-01
US20200325436A1 (en) 2020-10-15
KR20210149752A (ko) 2021-12-09
CA3134840A1 (fr) 2020-10-15
JP2022527383A (ja) 2022-06-01

Similar Documents

Publication Publication Date Title
Gramignoli et al. Isolation of human amnion epithelial cells according to current good manufacturing procedures
Edmonds et al. Testicular organoid formation is a property of immature somatic cells, which self-assemble and exhibit long-term hormone-responsive endocrine function
CN106085950A (zh) 分离卵巢中不同种类单细胞的方法
King et al. Alginate hydrogels for three-dimensional organ culture of ovaries and oviducts
Sardesai et al. Avoidance of maternal cell contamination and overgrowth in isolating fetal chorionic villi mesenchymal stem cells from human term placenta
Pozzobon et al. Isolation of c-Kit+ human amniotic fluid stem cells from second trimester
Lin et al. Monitoring cancer cell invasion and T-cell cytotoxicity in 3D culture
Czupalla et al. Collagenase-based single cell isolation of primary murine brain endothelial cells using flow cytometry
Nemeth et al. A practical guide to culturing mouse and human bone marrow stromal cells
Crosby et al. A novel in vitro 3D model and computational pipeline to quantify the vasculogenic potential of iPSC-derived endothelial progenitors
Picken et al. A Monte Carlo framework for managing biological variability in manufacture of autologous cell therapy from mesenchymal stromal cells therapies
CN117511880B (zh) 肿瘤体外原位模型的构建方法、培养基及体外应用
JP2023553838A (ja) 個人化された医薬品及び薬剤の開発で使用される有機マイクロ球状体
Roelofsen et al. Protocol for ex vivo culture of patient-derived tumor fragments
US20200325436A1 (en) Systems and Methods For Isolating Microvessels From Adipose Tissue
Wrzesinski et al. Clinostat 3D cell culture: protocols for the preparation and functional analysis of highly reproducible, large, uniform spheroids and organoids
Striedinger et al. Purification and preservation of satellite cells from human skeletal muscle
Yang et al. An improved method for the isolation and culture of rat epidermal stem cells
McNeil Direct introduction of molecules into cells
Matalová et al. Cell proliferation and apoptosis in the primary enamel knot measured by flow cytometry of laser microdissected samples
Liang et al. Protocols for isolation and characterization of mouse placental hemogenic endothelial cells
Robin et al. Preparation of hematopoietic stem and progenitor cells from the human placenta
Mirsaidi et al. Preparation and Osteogenic Differentiation of Scaffold‐Free Mouse Adipose‐Derived Stromal Cell Microtissue Spheroids (ASC‐MT)
Ilic et al. Isolation of human placental fibroblasts
Sandovici et al. Protocol to isolate and culture primary mouse feto-placental endothelial cells

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20211022

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0035300000

Ipc: C12M0001000000

A4 Supplementary search report drawn up and despatched

Effective date: 20221206

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 5/077 20100101ALI20221130BHEP

Ipc: A61K 35/35 20150101ALI20221130BHEP

Ipc: C12M 1/00 20060101AFI20221130BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20230704